Apr 09, 2020 - Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
Apr 17, 2020 - The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Apr 28, 2020 - Earnings Data Deluge
Apr 02, 2020 - Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Apr 03, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Apr 06, 2020 - Top Stock Reports for J&J, Merck, Novartis & Others
Apr 13, 2020 - J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
Apr 13, 2020 - The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.
Apr 20, 2020 - Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.